Background/Objectives: Induction of anti-SARS-CoV-2 antibodies by COVID-19 vaccination reduces morbidity and mortality, but immune responses may be compromised in people living with HIV (PLWH). The aims of the current study were to determine whether viral suppression (VS) or immune reconstitution (IR) in PLWH directly affected their ability to produce effective levels of anti-SARS-CoV-2 antibodies in mucosal secretions or blood induced by vaccination. Methods: Anti-SARS-CoV-2 spike IgG, IgA and secretory IgA (SIgA) antibodies and their avidities were measured by ELISA in HIV-negative healthy controls (HC; n=49) and PLWH (n=94) using stimulated oral fluid (SOF) and serum. Frequencies of CD4/CD8 T cells and their expression of exhaustion/senescence were determined by flow cytometry. Cytokine levels were measured by cytokine bead arrays. Results: We showed that higher HIV burden negatively impacted the levels of systemic and mucosal anti-SARS-CoV-2 spike IgG antibodies produced. This differential IgG antibody production was unaffected by the IR status, antiretroviral therapy duration or by T cell exhaustion/senescence. PLWH elicited higher anti-SARS-CoV-2 spike IgA antibodies both in peripheral blood and oral mucosa, and secretory IgA (SIgA) antibodies in the oral mucosa. PLWH with higher HIV burdens elicited lower IgG avidity but the IgA avidity indices remained unaffected. PLWH expressed higher levels of innate immunity cytokines irrespective of the HIV burden in the oral mucosa. Conclusions: Significantly fewer breakthrough infections in PLWH compared with HC, along with high IgA/SIgA antibodies and increased innate immunity cytokines in the SOF suggests a potential role for mucosal immunity in the immunopathogenesis of COVID-19.
Background/Objectives: The induction of anti-SARS-CoV-2 antibodies by COVID-19 vaccination reduces morbidity and mortality, but immune responses may be compromised in people living with HIV (PLWH). The aims of the current study were to determine whether viral suppression (VS) or immune reconstitution (IR) in PLWH directly affected their ability to produce effective levels of anti-SARS-CoV-2 antibodies in mucosal secretions or blood induced by vaccination. Methods: Anti-SARS-CoV-2 spike IgG, IgA and secretory IgA (SIgA) antibodies and their avidities were measured by ELISA in HIV-negative healthy controls (HC; n = 49) and PLWH (n = 94) using stimulated oral fluid (SOF) and serum. Frequencies of CD4/CD8 T cells and their expression of exhaustion/senescence were determined by flow cytometry. Cytokine levels were measured by cytokine bead arrays. Results: We showed that higher HIV burden negatively impacted the levels of systemic and mucosal anti-SARS-CoV-2 spike IgG antibodies produced. This differential IgG antibody production was unaffected by IR status, antiretroviral therapy duration or T cell exhaustion/senescence. PLWH elicited higher anti-SARS-CoV-2 spike IgA antibodies both in peripheral blood and oral mucosa and highr secretory IgA (SIgA) antibodies in the oral mucosa. PLWH with higher HIV RNA copies elicited lower IgG avidity but the IgA avidity indices remained unaffected. PLWH expressed higher levels of innate immunity cytokines in the oral mucosa, irrespective of the HIV RNA copies. Conclusions: Significantly fewer breakthrough infections in PLWH compared with HC, along with high IgA/SIgA antibodies and increased innate immunity cytokines in the SOF, suggest a potential role for mucosal immunity in the immunopathogenesis of COVID-19.
The entry of SARS-CoV-2 via the mucosal surfaces of the upper respiratory tract, including the oral cavity, may be influenced by innate and adaptive immunity. We aimed to determine whether antibodies in secretions might influence the SARS-CoV-2 burden and thus the severity of infection. Blood and stimulated oral fluid (SOF) samples were collected at recruitment (d0) from 173 participants and sequentially at d14, d30 and d90 from 52 participants. Anti-SARS-CoV-2 spike antibodies of the IgG, IgA and SIgA isotypes were detected by ELISA. SARS-CoV-2 RNA copies were quantified by RT-PCR. SARS-CoV-2 RNA copies became negative by d14 in most subjects. At d14, 5/18 SOF samples continued to be RT-PCR-positive. Serum/SOF IgG antibodies were detected in all patients; IgG/IgA/SIgA antibodies increased by d14 and decreased by d90. At d0 and d14, SOF RNA copies were negatively correlated with SOF/serum IgG and with SOF IgA/SIgA antibodies. Higher SOF antibodies were significantly associated with a more rapid decline in SARS-CoV-2 burden. SARS-CoV-2 RNA copies and spike-specific antibodies showed differential trends during the major and minor COVID-19 waves in India. Avidity indices for SOF IgG/IgA antibodies declined by d90. Taken together, our data suggest a potential functional role for SOF anti-SARS-CoV-2 spike antibodies in clearing SARS-CoV-2 from the oral mucosa.
Entry of SARS-CoV-2 via mucosal surfaces of the upper respiratory tract including the oral cavity may be influenced by innate and adaptive immunity. We aim to determine whether antibodies in secretions might influence the SARS-CoV-2 burden and thus the severity of infection. Blood and stimulated oral fluid (SOF) samples were collected at recruitment (d0) from 173 patients, and sequentially at d14, d30 and d90 from 52 SARS-CoV-2 RT-PCR-confirmed patients. Anti-SARS-CoV-2 spike antibodies of IgG, IgA and SIgA isotypes were detected by ELISA. SARS-CoV-2 RNA copies were quantified by RT-PCR. SARS-CoV-2 RNA copies become negative by d14 in most subjects. At d14, 5/18 SOF samples continued to be RT-PCR positive. Serum/SOF IgG antibodies were detected in all patients; IgG/IgA/SIgA antibodies increased by d14 and decreased by d90. At d0 and d14, SOF RNA copies were negatively correlated with SOF/serum IgG and with SOF IgA/SIgA antibodies. Higher SOF antibodies were significantly associated with a more rapid decline in SARS-CoV-2 burden. SARS-CoV-2 RNA copies and spike-specific antibodies show differential trends during the major and minor COVID-19 waves in India. Avidity indices for SOF IgG/IgA antibodies declined by d90. Taken together our data suggests a potential functional role for SOF anti-SARS-CoV-2 spike antibodies in reducing the SARS-CoV-2 burden.